BX Form 4: Director Reginald Brown receives 1,150 deferred restricted shares
Rhea-AI Filing Summary
Reginald J. Brown, a director of Blackstone Inc. (BX), received a grant of 1,150 deferred restricted common shares on September 15, 2025 under the Amended and Restated 2007 Equity Incentive Plan. The grant carries a $0 purchase price and will vest and result in delivery of the underlying shares on September 15, 2026, contingent on Mr. Browns continued service on Blackstones board.
Following this reported transaction, Mr. Brown beneficially owned 19,501 shares. The Form 4 was signed by Victoria Portnoy as attorney-in-fact on September 17, 2025 and includes an Exhibit 24 power of attorney.
Positive
- Director alignment: Grant of 1,150 deferred restricted shares aligns the reporting person's interests with shareholders.
- Retention feature: Vesting is tied to continued board service through September 15, 2026, supporting director retention.
Negative
- None.
Insights
TL;DR: A routine director equity award aligning compensation with continued board service; not immediately dilutive.
The filing documents a director-level grant of 1,150 deferred restricted shares that vest in one year subject to continued board service. Such awards are common for non-employee directors to align interests with shareholders and retain board members. The award price is $0 and the shares are deferred until vesting, so there is no immediate cash transaction and the shares are not presently exercisable. Beneficial ownership after the grant is reported as 19,501 shares. This disclosure is procedural and typical for director compensation programs and does not by itself indicate material corporate change.
TL;DR: One-year deferred share grant for a director; standard retention/alignments terms.
The transaction reflects a grant under the companys 2007 Equity Incentive Plan with vesting on September 15, 2026 contingent on continued service. Deferred restricted shares with a $0 price indicate a time-based equity award rather than a purchase or option. The quantum, 1,150 shares, should be evaluated relative to typical director grants at the firm but is reported here as part of normal governance disclosure. No derivative instruments or dispositions are reported.
FAQ
What transaction was reported for Blackstone Inc. (BX)?
When will the granted shares vest and be delivered?
What was the price of the grant reported on the Form 4?
How many shares does the reporting person own after the transaction?
Who signed the Form 4 and is there an exhibit attached?